GlassScriptPhysician profile
Eric M Goddard
NPI 1053824763
$3,456.40
in general payments reported to CMS, 2019-2025
27 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.51 · 2022: $26.67 · 2023: $947 · 2024: $1,116 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,376.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $847.83 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $469.40 | 2023-2025 | Dupixent |
| Genzyme Corporation | $341.56 | 2023-2025 | |
| Glaxosmithkline, LLC. | $276.81 | 2023-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.29 | 2023-2025 | Ofev, Jascayd |
| Baxter Healthcare | $155.50 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $147.01 | 2023-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $141.22 | 2023-2025 | |
| Inogen, INC. | $87.99 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Takeda Pharmaceuticals U.S.A., INC. | $86.22 | 2024-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $81.39 | 2023-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $70.00 | 2024-2025 | Winrevair, Recarbrio, Zerbaxa |
| Mylan Specialty L.P. | $63.08 | 2022-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $58.34 | 2024-2025 | Acthar |
| Abbott Laboratories | $53.51 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $45.97 | 2023-2024 | Wakix |
| Axsome Therapeutics, INC. | $39.40 | 2023-2025 | Sunosi |
| Amgen INC. | $38.87 | 2024-2025 | Tezspire, Tavneos |
| United Therapeutics Corporation | $36.85 | 2025 | Tyvaso |
| Viatris Specialty LLC | $33.45 | 2025 | Yupelri |
| Philips North America LLC | $33.33 | 2022-2024 | (Ak6) Vest Therapy |
| Lilly USA, LLC | $28.36 | 2025 | Zepbound, Mounjaro |
| Ani Pharmaceuticals, INC. | $24.79 | 2025 | Purified Cortrophin Gel |
| Insmed, INC. | $21.66 | 2025 | Arikayce |
| Pfizer INC. | $19.26 | 2025 | |
| Altathera Pharmaceuticals LLC | $18.05 | 2023 | Sotalol Hydrochloride |
| Electromed, INC. | $15.26 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Goddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.